PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Analyze analyst forecasts for the company and compare them with competitors.
1.01M
No peer data available for comparison.
-202.40K
No peer data available for comparison.
-1.35
No peer data available for comparison.
-35.97M
No peer data available for comparison.
-202.40K
No peer data available for comparison.
37.50M
No peer data available for comparison.
Analyze DCF forecasts for the company and compare them with competitors.
1.03M
Worse than EXEL's revenue of 1.61B.
-9.97%
Worse than EXEL's revenue growth rate of 12.27%.
-33.41M
Worse than EXEL's ebitda of 222.36M.
-3243.20%
Worse than EXEL's ebitda margin of 13.80%.
-34.10M
Worse than EXEL's ebit of 201.48M.
-3311.07%
Worse than EXEL's ebit margin of 12.51%.
699.00K
Better than EXEL's depreciation of 20.88M.
108.91M
Worse than EXEL's total cash of 1.31B.
10573.79%
Better than EXEL's cash as percentage of revenue of 81.22%.
No Data
No DCF data available for this metric in the selected year.
No Data
No DCF data available for this metric in the selected year.
No Data
No DCF data available for this metric in the selected year.
No Data
No DCF data available for this metric in the selected year.
10.13M
Better than EXEL's accounts payable of 32.67M.
983.50%
Worse than EXEL's payables as percentage of revenue of 2.03%.
-366.00K
Worse than EXEL's capital expenditure of -138.46M.
-35.53%
Better than EXEL's capex as percentage of revenue of -8.59%.
4.99%
Better than EXEL's weighted average cost of capital (wacc) of 6.62%.
5.02%
Better than EXEL's cost of equity of 6.67%.
4.08%
Better than EXEL's cost of debt of 4.26%.
-0.23
Better than EXEL's beta of 0.51.
30.07M
Better than EXEL's diluted shares outstanding of 321.46M.
1.57M
Better than EXEL's total debt of 189.94M.
49.31M
Worse than EXEL's total equity of 11.10B.
50.89M
Worse than EXEL's total capital of 11.29B.
3.09%
Worse than EXEL's debt weighting of 1.68%.
96.91%
Worse than EXEL's equity weighting of 98.32%.
-32.98M
Worse than EXEL's ebiat of 156.72M.
-28.05M
Worse than EXEL's unlevered free cash flow of 109.60M.
2.00%
Worse than EXEL's long-term growth rate of 4.00%.
No Data
No DCF data available for this metric in the selected year.
No Data
No DCF data available for this metric in the selected year.
-71.33M
Worse than EXEL's net debt of -73.05M.
71.33M
Worse than EXEL's equity value of 8.24B.
2.37
Worse than EXEL's equity value per share of 25.62.
View analysts' price targets and recommendations, and compare them with competitors.
$11.07
Analysts expect the stock price to increase by 521.91%.
Buy
Positive consensus among analysts.